Publications
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer2020 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report2020 | Faculty of Medicine in Pilsen
- Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib2020 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy2017 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer2017 | Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science, First Faculty of Medicine
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy2016 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
Loading network view...